NEW GENERIC DRUG ALLIANCE AFFECTING LOBLAW STOCK

Jan 30, 2018

By Michael Kramer

Share on

A long-awaited deal to reduce generic drug costs has led to Desjardins Group and R-B-C downgrading their outlook for Loblaw Companies stock.

Desjardins has lowered its target price for the grocery-and-pharmacy retailer to 76-dollars per share from 84-dollars – and cut its recommendation to hold.
An analyst with R-B-C Dominion Securities also dropped her target price from 87 to 84-dollars.

The change comes after the alliance representing the provinces, territories and federal government reached an agreement with the Canadian Generic Pharmaceutical Association – that will see the prices of nearly 70 generic drugs discounted by up to 90 per cent – of their brand name equivalents.

Join Our Fan Club
Coverage Area
Downtown Toronto
96.7FM
Toronto HD
96.3 HD-2
Kingston to Windsor, Parry Sound to Pittsburgh
AM740
ZoomerRadio Logo

Recently Played: